For research use only. Not for therapeutic Use.
Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain[1][2][3].
| Catalog Number | I045116 |
| CAS Number | 1233229-75-8 |
| Synonyms | (2S)-2-[[1-ethyl-6-(4-methylphenoxy)benzimidazol-2-yl]methylamino]propanamide |
| Molecular Formula | C20H24N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H24N4O2/c1-4-24-18-11-16(26-15-7-5-13(2)6-8-15)9-10-17(18)23-19(24)12-22-14(3)20(21)25/h5-11,14,22H,4,12H2,1-3H3,(H2,21,25)/t14-/m0/s1 |
| InChIKey | ZYUAASICHDTDEK-AWEZNQCLSA-N |
| SMILES | CCN1C2=C(C=CC(=C2)OC3=CC=C(C=C3)C)N=C1CNC(C)C(=O)N |
| Reference | [1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. [2]. Yoshihiro OYAMADA, et al. External medicinal preparation containing N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alanineamide for treating and/or preventing peripheral neuropathic pain. Patent AU2019306705. [3]. Hironori Kinoshita, et al. Preparation of N2-[(benzimidazol-2-yl or imidazo[4,5-b]pyridin-2-yl)methyl]amino acid amide derivatives as inhibitors of sensory neuron specific sodium channel (SNS). Patent AU2009331179. |
